Authors: Nicholson, RI Hutcheson, IR Harper, ME Knowlden, JM Barrow, D McClelland, RA Jones, HE Wakeling, AE Gee, JMW

Citation: Ri. Nicholson et al., Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer, ENDOCR-R CA, 8(3), 2001, pp. 175-182

Authors: Robertson, JF Nicholson, RI Bundred, NJ Anderson, E Rayter, Z Dowsett, M Fox, JN Gee, JMW Webster, A Wakeling, AE Morris, C Dixon, M

Citation: Jf. Robertson et al., Comparison of the short-term biological effects of 7 alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17 beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer, CANCER RES, 61(18), 2001, pp. 6739-6746

Authors: Howell, A Osborne, CK Morris, C Wakeling, AE

Citation: A. Howell et al., (Faslodex (TM)): development of a novel, "pure" antiestrogen (vol 89, pg 817, 2000), CANCER, 91(2), 2001, pp. 455-455

Authors: Wakeling, AE

Citation: Ae. Wakeling, Similarities and distinctions in the mode of action of different classes of antioestrogens, ENDOCR-R CA, 7(1), 2000, pp. 17-28

Authors: Howell, A Osborne, CK Morris, C Wakeling, AE

Citation: A. Howell et al., ICI 182,780 (Faslodex (TM)) - Development of a novel, "pure" antiestrogen, CANCER, 89(4), 2000, pp. 817-825